Abstract
HIV-1 integrase, a member of a polynucleotidyl transferases superfamily, catalyzes the insertion of the viral DNA into the genome of host cells. It has emerged as a potential target for developing anti-HIV agents. In the last two decades, a number of integrase inhibitors have been developed as potential anti-HIV therapeutics. Several integrase inhibitors have reached later stages of clinical trials including S-1360, L870,810, L870,812 and BMS-707035. Into the bargain, Raltegravir, Elvitegravir and Dolutegravir have been approved by FDA as anti-HIV agents. This review article summarizes the structural insights required for the inhibition of the HIV1 integrase in the context of clinically relevant HIV1 integrase inhibitors. Additionally, the structural features required for overcoming HIV resistance have been discussed. These insights will update the ongoing design of novel antiviral inhibitors.
Keywords: HIV resistance, HIV-1 integrase, Anti-HIV therapeutics, Novel antiviral inhibitors, Polynucleotidyl transferases, Viral DNA.
Current Topics in Medicinal Chemistry
Title:Structure Based Drug Design: Clinically Relevant HIV-1 Integrase Inhibitors
Volume: 18 Issue: 31
Author(s): Maninder Kaur, Ravindra K. Rawal*, Goutam Rath and Amit K. Goyal*
Affiliation:
- Department of Chemistry, Maharishi Markandeshwar (Deemed to be University), Mullana-133207, Haryana,India
- National Institute of Animal Biotechnology, Miyapur, Hyderabad 500049,India
Keywords: HIV resistance, HIV-1 integrase, Anti-HIV therapeutics, Novel antiviral inhibitors, Polynucleotidyl transferases, Viral DNA.
Abstract: HIV-1 integrase, a member of a polynucleotidyl transferases superfamily, catalyzes the insertion of the viral DNA into the genome of host cells. It has emerged as a potential target for developing anti-HIV agents. In the last two decades, a number of integrase inhibitors have been developed as potential anti-HIV therapeutics. Several integrase inhibitors have reached later stages of clinical trials including S-1360, L870,810, L870,812 and BMS-707035. Into the bargain, Raltegravir, Elvitegravir and Dolutegravir have been approved by FDA as anti-HIV agents. This review article summarizes the structural insights required for the inhibition of the HIV1 integrase in the context of clinically relevant HIV1 integrase inhibitors. Additionally, the structural features required for overcoming HIV resistance have been discussed. These insights will update the ongoing design of novel antiviral inhibitors.
Export Options
About this article
Cite this article as:
Kaur Maninder, Rawal K. Ravindra*, Rath Goutam and Goyal K. Amit *, Structure Based Drug Design: Clinically Relevant HIV-1 Integrase Inhibitors, Current Topics in Medicinal Chemistry 2018; 18 (31) . https://dx.doi.org/10.2174/1568026619666190119143239
DOI https://dx.doi.org/10.2174/1568026619666190119143239 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Capsid Assembly as a Point of Intervention for Novel Anti-viral Therapeutics
Current Pharmaceutical Biotechnology Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Targeted Multifunctional Lipid-Based Nanocarriers for Image-Guided Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Advances on Cyclin-dependent Kinases (CDKs) as Novel Targets for Antiviral Drugs
Current Drug Targets - Infectious Disorders Development of Calixarenes, Cyclodextrins and Fullerenes as New Platforms for Anti-HIV Drug Design: An Overview
Mini-Reviews in Medicinal Chemistry Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors
Current Topics in Medicinal Chemistry Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Epidemiological Profile of Naive HIV-1/AIDS Patients in Istanbul: The Largest Case Series from Turkey
Current HIV Research Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Avian Cytokines - An Overview
Current Pharmaceutical Design The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Current Drug Targets Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials